Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
-0.24%
)
US TECH 100
25,918.50
(
-0.14%
)
Dow Jones
49,442.56
(
-0.01%
)
Brent Oil
91.08
(
0.45%
)
Bitcoin
76,106.94
(
0.28%
)
News Focus
News Focus
Post# of 80490
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

investor maven

Send PM Follow Ignore
Followers 5
Posts 487
Boards Moderated 0
Alias Born 10/15/2013

investor maven

Re: lax20m post# 57484

Thursday, 12/18/2014 5:23:42 AM

Thursday, December 18, 2014 5:23:42 AM

Post# of 80490
Clinical Community never had doubts...

Lax,
I just had to respond - Dr Talpaz, Dr Cortez, etc. always supported the risk-benefit value of ponatinib. It's the FDA that was concerned, and yes, their opinion counts for a lot, but PLEASE stop claiming that the clinicians have a concern. Definitely not the leading CML experts.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today